#Israel #CollPlant #rhCollagen #Rehovot #dermal filler

CollPlant Biotechnologies Announces Positive Results from Non-Clinical Studies

CollPlant Biotechnologies, a leading name in regenerative and aesthetic medicine, has recently declared its positive findings from non-clinical evaluations of its innovative photocurable dermal and soft tissue filler. This development marks a notable leap in the field of aesthetic treatments, showcasing a unique integration of contouring precision, structural support, and tissue regeneration in a single product.

The core of the product lies in its proprietary technology utilizing non-animal recombinant human collagen (rhCollagen). By combining this advanced formulation with hyaluronic acid, CollPlant's filler offers both immediate impacts and enduring benefits to those seeking cosmetic enhancements. This viscoelastic gel is expertly administered through a fine needle, permitting practitioners to sculpt precise facial contours. The intelligent design includes a proprietary illumination device that activates the gel, allowing it to transform into a semi-solid, cohesive implant. This advanced format ensures the filler can withstand gravity and mechanical forces while retaining its intended shape.

Yehiel Tal, the CEO of CollPlant, emphasized the significance of this development. He stated, “The successful completion of our extensive non-clinical program is a critically important milestone for CollPlant. It enables us to enter the clinical development phase for our photocurable regenerative filler. By harnessing the exceptional characteristics of our rhCollagen technology, we are poised to redefine care in aesthetic medicine with a groundbreaking solution that delivers immediate contouring, support, and promotes natural tissue integration for long-lasting results.”

The thorough nature of CollPlant’s non-clinical program encompassed an extensive series of safety and performance evaluations. This included a rigorous one-year in vivo study which verified the product's long-term durability, as well as biocompatibility assessments that confirmed compliance with international standards. The positive results cultivated during these evaluations create a solid foundation for the impending clinical advancements.

Currently, CollPlant is poised to scale and optimize its manufacturing processes, ensuring that it is well-prepared as it transitions into clinical trials. The company's commitment to innovation and safety places it in a favorable position for future success in the dynamic aesthetic market.

In addition to enhancing aesthetic medicine, CollPlant is at the forefront of tissue engineering, focusing on 3D bioprinting technologies for tissues and organs. Their proprietary rhCollagen produced via plant-based genetic engineering not only serves the aesthetic field but also has far-reaching implications in tissue repair and organ manufacturing.

In a strategic move reflecting its dedication to expanding its market presence, CollPlant entered into a developmental and global commercialization partnership with Allergan in 2021. Allergan, a subsidiary of AbbVie, is recognized as a global leader in the dermal filler market, thus positioning CollPlant to tap into a robust distribution network.

The outlook for CollPlant Biotechnologies appears promising. With a strong foundation built from their non-clinical successes, the company sets its sights firmly on launching its innovative products into clinical and subsequent commercial realms. The coming months will be critical as they prepare to advance their product towards clinical use, offering physicians and patients a revolutionary alternative in aesthetic treatments.

For more insights into CollPlant’s ongoing developments and industry advancements, visit their website at CollPlant.